Europe’s medical devices industry saw a flat growth in deal activity during April 2021, when compared with the last 12-month average, led by $5bn acquisition of CA Healthcare Acquisition and LumiraDx, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 34 medical devices industry deals worth $6.3bn were announced for the region in April 2021, against the 12-month average of 34 deals.
Of all the deal types, venture financing saw most activity in April 2021 with 18 transactions, representing a 52.9% share for the region.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In second place was M&A with 13 deals, followed by private equity deals with three transactions, respectively capturing a 38.2% and 8.8% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $6.08bn, followed by venture financing deals totalled $245.8m.
Europe medical devices industry deals in April 2021: Top deals
The top five medical devices deals accounted for 97.7% of the overall value during April 2021.
The combined value of the top five medical devices deals stood at $6.18bn, against the overall value of $6.3bn recorded for the month.
The top five medical devices industry deals of April 2021 tracked by GlobalData were:
1) The $5bn merger of CA Healthcare Acquisition and LumiraDx
2) The $795m acquisition deal with Mobidiag by Hologic
3) AddLife’s $216.53m acquisition of Vision Ophthalmology Group
4) The $115m venture financing of CeQur by Credit Suisse Entrepreneur Capital, Endeavour Vision, Federated Hermes Kaufmann Fund, GMS Capital, Kingdon Capital Management, SchroderBank AG, Tandem Diabetes Care, VI Partners and Ypsomed
5) Cambridge Innovation Capital, Earlybird Venture Capital GmbHKG, Jonathan Milner, Koch Disruptive Technologies and Mercia Asset Management’s venture financing of Sense Biodetection for $50m.